Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Equitable Trust Co.

Equitable Trust Co. decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 28.5% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 3,583 shares of the medical research company’s stock after selling 1,428 shares during the quarter. Equitable Trust Co.’s holdings in Thermo Fisher Scientific were worth $2,216,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of TMO. AEGON ASSET MANAGEMENT UK Plc lifted its holdings in shares of Thermo Fisher Scientific by 0.9% in the 3rd quarter. AEGON ASSET MANAGEMENT UK Plc now owns 57,384 shares of the medical research company’s stock worth $35,472,000 after purchasing an additional 507 shares during the last quarter. Burt Wealth Advisors bought a new stake in Thermo Fisher Scientific in the third quarter valued at $205,000. Capital Performance Advisors LLP acquired a new position in shares of Thermo Fisher Scientific during the third quarter valued at $129,000. AIA Group Ltd increased its holdings in shares of Thermo Fisher Scientific by 1.8% in the 3rd quarter. AIA Group Ltd now owns 17,676 shares of the medical research company’s stock worth $10,934,000 after acquiring an additional 309 shares during the period. Finally, Verity Asset Management Inc. bought a new stake in Thermo Fisher Scientific in the 3rd quarter valued at about $283,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the transaction, the senior vice president now directly owns 12,736 shares in the company, valued at $7,134,197.76. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the sale, the senior vice president now directly owns 12,736 shares in the company, valued at $7,134,197.76. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the sale, the executive vice president now owns 16,663 shares in the company, valued at $9,333,946.08. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,150 shares of company stock worth $15,676,125. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.7 %

TMO stock opened at $551.74 on Friday. The business’s 50-day simple moving average is $593.95 and its 200 day simple moving average is $583.63. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The company has a market cap of $211.04 billion, a PE ratio of 34.59, a price-to-earnings-growth ratio of 3.70 and a beta of 0.79. Thermo Fisher Scientific Inc. has a twelve month low of $437.26 and a twelve month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.03. The firm had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business’s revenue for the quarter was up .2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.69 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be issued a dividend of $0.39 per share. The ex-dividend date is Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. Thermo Fisher Scientific’s payout ratio is presently 9.78%.

Analysts Set New Price Targets

TMO has been the topic of a number of recent analyst reports. Morgan Stanley lifted their price target on Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a report on Friday, September 20th. UBS Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a research report on Monday, September 16th. TD Cowen lifted their price objective on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Bank of America increased their target price on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Finally, Wells Fargo & Company reduced their price target on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $649.33.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.